Cytokinetics's Total Assets for the quarter that ended in Mar. 2024 was $808.08 Mil.
During the past 12 months, Cytokinetics's average Total Assets Growth Rate was -16.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 44.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 75.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 46.90% per year.
During the past 13 years, Cytokinetics's highest 3-Year average Total Assets Growth Rate was 209.70%. The lowest was -50.30%. And the median was 16.70%.
The historical data trend for Cytokinetics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cytokinetics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cytokinetics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cytokinetics Total Assets Related Terms
Thank you for viewing the detailed overview of Cytokinetics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTK has been successfully added to your 